Incyte Corp. (1INCY)
MTA
Real-time Data
07:00 AM
Day's Range
106.2552 wk Range
72.70Overview - 1INCY - Incyte Corp.
Key Statistics
Valuation
Enterprise Value
15.41B
P/E (Trailing)
‪15.76‬
PEG Ratio
‪0.39‬
Price / Sales (TTM)
‪3.78‬
Price / Book
‪3.92‬
EV / EBITDA
‪9.04‬
Profitability
Gross Margin
‪93.72%‬
Profit Margin
‪27.70%‬
Operating Margin
‪41.89%‬
Return on Assets
‪16.83%‬
Return on Equity
‪30.66%‬
Ownership
Shares Outstanding
200.97M
Float
170.72M
Held by Insiders
‪1.84%‬
Held by Institutions
‪103.49%‬
Price stats
Beta
‪0.77‬
50-Day Avg
‪107.08‬
200-Day Avg
‪91.74‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 1INCY - Incyte Corp.
Peers - 1INCY - Incyte Corp.
Peer Comparison
Compared with companies in Biotechnology listed on MTA.
- 1INCYMTAIncyte Corp.17.89BMarket Cap+32.92%52-week change15.77P/E (Trailing)‪27.70%‬Profit Margin
- 1VRTXMTAVertex Pharmaceuticals Incorporated Common Stock107.27BMarket Cap+27.72%52-week change30.40P/E (Trailing)‪34.99%‬Profit Margin
- 1REGNMTARegeneron Pharmaceuticals, Inc.73.52BMarket Cap+30.66%52-week change19.47P/E (Trailing)‪27.86%‬Profit Margin
- 1ALNYMTAAlnylam Pharmaceuticals, Inc.45.81BMarket Cap-73.35%52-week change43.84P/E (Trailing)‪16.12%‬Profit Margin
- 1INSMMTAInsmed Inc30.28BMarket Cap-19.46%52-week change-16.17P/E (Trailing)‪-76.94%‬Profit Margin
- 1CGMTAThe Carlyle Group Inc.18.64BMarket Cap-40.10%52-week change42.38P/E (Trailing)‪13.01%‬Profit Margin
- 1RVMDMTARevolution Medicines, Inc.12.75BMarket Cap+72.89%52-week change-28.65P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - 1INCY - Incyte Corp.
About
Incyte Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company’s current portfolio centers on hematology, oncology, and inflammation and autoimmunity, with products and programs aimed at treating cancers, blood disorders, and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
